SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Astrazeneca Pharma India Ltd

BSE: 506820 NSE: ASTRAZEN ISIN: INE203A01020
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Astrazeneca Pharma India Ltd belong to?
Astrazeneca Pharma India Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Astrazeneca Pharma India Ltd a good quality company?
Astrazeneca Pharma India Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Astrazeneca Pharma India Ltd undervalued or overvalued?
Astrazeneca Pharma India Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Astrazeneca Pharma India Ltd a good buy now?
Astrazeneca Pharma India Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd revenue growth is 32.5% for FY-2025 , which is above its 5 year CAGR of 15.6% , indicating faster growth.
Q.2 Gross Profit margin of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Gross profit margin which is the profit after deduction of direct costs, is 17% for FY-2025 , which is in line with its 5 year median of 17% , indicating stable margins.
Q.3 Operating Profit Margin of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 14.82% for FY-2025 , which is in line with its 5 year median of 14.82% indicating stable margins.
Q.4 Net Profit Margin of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Net Profit Margin is 6.74% for FY-2025 , is below with its 5 year median of 9.9%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 17 17
Operating Profit Margin 14.82 14.82
Net Profit Margin 6.74 9.9
Q.5 Return on Asset of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Return on Asset is 7.43%, which is below its 5 year historical median of 9.37%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Return on equity is 15.73% for FY-2025 , which is below its historical median of 18.13%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Return on capital employed is 21.29% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Cash conversion cycle is 50 days, above its historical median of 6 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.11 0.99
ROE 15.73 18.13
ROCE 21.29 24.49
Cash Conversion Cycle 50 days 6 days
Q.9 Debt to Equity ratio of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Astrazeneca Pharma India Ltd?
Astrazeneca Pharma India Ltd Debt to cash flow from operations is 0 , which is at a healthy level, indicating the business is able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Astrazeneca Pharma India Ltd?
Promoters hold 75.00% of the Astrazeneca Pharma India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Astrazeneca Pharma India Ltd vs industry peers?
Astrazeneca Pharma India Ltd revenue CAGR is 15.59% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,716.3 137.1
Gross Profit 291.7 15.1
Operating Profit 254 16
Net Profit 116 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.11 0.8
ROE 15.73 8.91
ROCE 21.29 11.59
Cash Conversion Cycle (days) 49.9 76

Valuation & price assessment

Q.1 Stock return of Astrazeneca Pharma India Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 22.3% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 22.3% 19.8% 39.4% 2.8%
Q.3 Valuation ratios of Astrazeneca Pharma India Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 108.49 128.69 40.28
Price to Book 26.21 23.39 2.77
Price to Sales 10.01 10.87 2.65
EV to EBITDA 65.59 68.61 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Pfizer
6. Wockhardt
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Acutaas Chemicals
10. Piramal Pharma
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×